- Home
- AGAE vs ACXP Comparison
AGAE vs ACXP Comparison
Compare AGAE & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- ACXP
- Stock Information
- Founded
- AGAE 2017
- ACXP 2017
- Country
- AGAE United States
- ACXP United States
- Employees
- AGAE N/A
- ACXP N/A
- Industry
- AGAE Cable & Other Pay Television Services
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- AGAE Telecommunications
- ACXP Health Care
- Exchange
- AGAE Nasdaq
- ACXP Nasdaq
- Market Cap
- AGAE 115.6M
- ACXP 8.4M
- IPO Year
- AGAE N/A
- ACXP 2021
- Fundamental
- Price
- AGAE $1.63
- ACXP $0.47
- Analyst Decision
- AGAE
- ACXP Strong Buy
- Analyst Count
- AGAE 0
- ACXP 2
- Target Price
- AGAE N/A
- ACXP $10.00
- AVG Volume (30 Days)
- AGAE 126.0K
- ACXP 18.7M
- Earning Date
- AGAE 07-07-2025
- ACXP 08-08-2025
- Dividend Yield
- AGAE N/A
- ACXP N/A
- EPS Growth
- AGAE N/A
- ACXP N/A
- EPS
- AGAE N/A
- ACXP N/A
- Revenue
- AGAE $8,975,246.00
- ACXP N/A
- Revenue This Year
- AGAE N/A
- ACXP N/A
- Revenue Next Year
- AGAE N/A
- ACXP N/A
- P/E Ratio
- AGAE N/A
- ACXP N/A
- Revenue Growth
- AGAE 1.52
- ACXP N/A
- 52 Week Low
- AGAE $0.70
- ACXP $0.30
- 52 Week High
- AGAE $3.79
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- AGAE 36.59
- ACXP 52.38
- Support Level
- AGAE $1.67
- ACXP $0.45
- Resistance Level
- AGAE $1.80
- ACXP $0.59
- Average True Range (ATR)
- AGAE 0.28
- ACXP 0.08
- MACD
- AGAE -0.16
- ACXP -0.01
- Stochastic Oscillator
- AGAE 0.59
- ACXP 27.06
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.